Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (Nasdaq: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. Its investigational portfolio targets α4β7, TL1A and IL-23, with candidates being developed as monotherapies and… From the company’s description.
In fiscal 2025, Spyre Therapeutics, Inc. reported a net loss of $155.20M. Operations used $169.25M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Spyre Therapeutics, Inc. does
In the company’s own words
Spyre Therapeutics, Inc. (Nasdaq: SYRE) is a clinical-stage biotechnology company developing long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. Its investigational portfolio targets α4β7, TL1A and IL-23, with candidates being developed as monotherapies and paired combinations. SPY001 targets α4β7 for IBD, SPY002 targets TL1A for IBD, SPY003 targets IL-23 for IBD, and SPY072 targets TL1A for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Combination programs pair these antibody mechanisms for IBD. The company evaluates its IBD candidates and combinations in the SKYLINE Phase 2 platform trial and SPY072 in the SKYWAY Phase 2 basket trial. Spyre’s candidates are designed with extended half-lives and high-concentration formulations to support less frequent subcutaneous maintenance dosing. As of December 31, 2025, the company had 102 full-time employees. Spyre changed its name from Aeglea BioTherapeutics in November 2023 and obtained its core programs through licensing agreements. Its website is https://www.spyre.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WALTHAM, MA
- Fiscal year end
- December
- CIK
- 1636282
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Spyre Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Spyre Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Spyre Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Spyre Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Spyre Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”